Definition: Acute, idiopathic peripheral facial nerve (CN VII) palsy

The Facial Nerve (CN VII):

  • Provides parasympathetic innervation to the submandibular salivary glands, sublingual salivary glands, and lacrimal glands
  • Conveys taste sensations from the anterior two-thirds of the tongue via sensory fibers
  • Controls the muscles of facial expression
  • Pearls:
    • The right facial nerve controls the right face, and the left facial nerve controls the left face
    • The upper muscles of facial expression are innervated by fibers from both the ipsilateral as well as contralateral cortex; in other words, innervation to each side of the forehead is from both motor cortices
    • Therefore, a peripheral lesion should completely affect one side of the face, while a central lesion should spare the motor function of the forehead, since the contralateral cortex supplies fibers to the affected side

Etiology:

  • Idiopathic by definition
  • See differential for possible etiologies
  • Mechanism: edema, inflammation, and nerve degeneration at the geniculate ganglion within stylomastoid foramen which can lead to compression and possible ischemia and demyelination

Epidemiology:

  • Incidence of 15-40 / 100,000
  • Affects men and women equally
  • All ages are affected, with peak incidence in the 30s to 50s
  • Risk factors include pregnancy, diabetes, and previous episode(s) of Bell’s palsy

History:

  • Sudden onset unilateral facial droop, incomplete eyelid closure, and loss of forehead muscle tone
  • Onset over the course of hours and peaks within three to seven days
  • Facial asymmetry with disappearance of nasolabial fold and facial creases
  • Eye irritation from decreased tearing and inability to close the affected eye
  • Abnormal taste and drooling from the affected side
  • Subjective “numbness” of the affected side due to paralysis but preserved facial sensation

Physical:

  • Unilateral eyebrow sagging and inability to close the eye
  • Disappearance of unilateral facial creases, especially nasolabial fold and forehead furrows
  • Drooping at the corner of the mouth
  • Although absolute tear production may be decreased, the inability to blink may allow tears to spill from the eye
  • Preservation of the upper muscles of facial expression suggests a central cause
  • Assess bilateral ear canals with otoscopy
  • Assess parotid gland for masses
  • Perform a full neurological exam: should expect an otherwise normal neurological exam including all other cranial nerves and extremity motor function

https://www.health.harvard.edu/pain/bells-palsy-overview

Differential:

  • Bell’s palsy is a diagnosis of exclusion
  • Herpes Zoster (Ramsay Hunt syndrome): evaluate for vesicles, tinnitus, or vertigo
  • Infectious mononucleosis: evaluate for pharyngitis, posterior cervical adenopathy, or viral prodrome
  • Guillain-Barré Syndrome: usually presents with ascending motor weakness
  • Lyme Disease: history of rash or tick bite in endemic area
  • Otitis Media
  • Cholesteatoma
  • Parotid gland masses
  • Multiple Sclerosis: usually bilateral peripheral CN VII palsy
  • Sarcoidosis: usually bilateral peripheral CN VII palsy
  • Brainstem events (mass, bleed, infarct): will usually present with other cranial nerve palsies
  • Basilar artery aneurysm
  • Stroke
  • Tumors: consider parotid, bone, metastatic masses, or acoustic neuroma
  • Trauma: skull fracture or penetrating facial injury

Diagnosis:

  • For high pre-test probability of Bell’s Palsy, there is no indication for labs or imaging: diagnosis is based on history and physical
  • If you suspect another cause of facial nerve palsy, order targeted labs and/or imaging (e.g. Lyme titers or monospot if high suspicion for viral etiology)
  • Consider blood glucose in Bell’s Palsy patients with other diabetic risk factors as 10% of Bell’s Palsy patients have diabetes

ED Management:

  • Glucocorticoids may hasten recovery if started within 72 hours of symptom onset: 1mg/kg prednisone (or 60 to 80 mg) PO daily for 7 days (pediatric dose: 2mg/ kg/ day PO [max 60mg])
    • NNT to prevent one incomplete recovery = 10
    • No clear regimen, most studies use 7-10 days of PO prednisone
  • Anti-viral therapy with steroids may improve functional nerve recovery if started within 72 hours of symptom onset: valacyclovir 1000 mg PO daily for 7 days (pediatric dose: 20mg/ kg TID PO)
    • Low quality evidence that antivirals with glucocorticoids is superior to glucocorticoids alone
    • American Academy of Neurology recommends offering antivirals while explaining limited evidence but also limited harm
  • Corneal damage may occur due to incomplete eye closure
    • prescribe lubricating and hydrating ophthalmic ointment and/ or drops (artificial tears qhs and prn dryness/ irritation in affected eye)
    • instruct patient on wearing eye patch at night on affected eye

Prognosis:

  • In the Copenhagen Facial Nerve Study (2002), 2,570 cases of untreated peripheral facial nerve palsy were studied during a period of 25 years (1,701 cases of Bell’s palsy)
  • 71% of Bell’s palsy patients returned to baseline function in three weeks without treatment
  • Almost all patients noticed some improvement in three to four months
  • Prognosis is related to initial severity: with incomplete lesions, 94% returned to baseline whereas of those with complete lesions, 60% returned to baseline

Patient Education and Discharge Instructions:

  • While not life threatening, Bell’s palsy can cause significant distress
  • Symptoms peak within three to seven days, and almost always improve somewhat by 3 months
  • With incomplete lesions, ~95% return to baseline; with complete lesions, ~60% return to baseline
  • Prescribe artificial tears during the day and ointments with eye patch at night
  • 1 week follow-up with outpatient neurologist for management of symptoms and to monitor recovery

Take Home Points:

  • Bell’s palsy is acute, peripheral, and idiopathic
  • A non-acute onset of symptoms (gradual onset of more than two weeks duration) should suggest a mass lesion
  • Perform a very careful thorough exam, including full neurological exam, dermatological exam (evaluate for vesicles or rash), and ENT exam (evaluate for pharyngitis, posterior cervical adenopathy, otitis media, deafness)
  • No role for labs or imaging, but deviation from the typical history and physical should prompt further workup
  • Start glucocorticoids and antivirals in the ED if symptoms started within 72 hours and if there are no contraindications
  • Provide patient education about the prognosis and eye care to prevent corneal abrasions
  • Arrange for close neurology follow-up

References:

Zhang W, Xu L, Luo T, Wu F, Zhao B, Li X. The etiology of Bell’s palsy: a review. Journal of Neurology. 2019. doi:10.1007/s00415-019-09282-4.

Tiemstra JD, Khatkhate N. Bell’s Palsy: Diagnosis and Management. American Family Physician. https://www.aafp.org/afp/2007/1001/p997.html. Published October 1, 2007. Accessed May 22, 2019.

Gronseth GS, Paduga R. Evidence-based guideline update: Steroids and antivirals for Bell palsy: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2012;79(22):2209-2213. doi:10.1212/wnl.0b013e318275978c.

Madhok VB, Gagyor I, Daly F, et al. Corticosteroids for Bells palsy (idiopathic facial paralysis). Cochrane Database of Systematic Reviews. 2016. doi:10.1002/14651858.cd001942.pub5.

Gagyor I, Madhok VB, Daly F, et al. Antiviral treatment for Bells palsy (idiopathic facial paralysis). Cochrane Database of Systematic Reviews. 2015. doi:10.1002/14651858.cd001869.pub6.

Loomis C, Mullen MT. Differentiating Facial Weakness Caused by Bell’s Palsy vs. Acute Stroke. Journal of Emergency Medical Services. https://www.jems.com/articles/print/volume-39/issue-5/features/differentiating-facial-weakness-caused-b.html. Published May 7, 2014. Accessed May 22, 2019.

Peitersen E. Bell’s palsy: the spontaneous course of 2,500 peripheral facial nerve palsies of different etiologies.  Acta Otolaryngol Suppl.  2002:4-30.

Schaider et al. Rosen & Barkin’s 5-Minute Emergency Medicine Consult, 5th Edition.  Wolters Kluwer.